/Gilead%20Sciences%2C%20Inc_%20pills-by%20%20Marc%20Bruxelle%20via%20Shutterstock.jpg)
Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs. Valued at $152.8 billion by market cap, the company’s primary areas of focus include HIV, AIDS, liver disease, and severe cardiovascular and respiratory conditions. The HIV giant is expected to announce its fiscal third-quarter earnings for 2025 after the market closes on Thursday, Oct. 30.
Ahead of the event, analysts expect GILD to report a profit of $2.15 per share on a diluted basis, up 6.4% from $2.02 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.